Demonstrating Comparability of Stability Profiles Using Statistical Equivalence Testing - The authors present an approach for testing statistical equivalence of two stability profiles. - BioPharm

ADVERTISEMENT

Demonstrating Comparability of Stability Profiles Using Statistical Equivalence Testing
The authors present an approach for testing statistical equivalence of two stability profiles.


BioPharm International
Volume 24, Issue 3, pp. 36-42

Step 2: Study design and determining sample size


Table 1
As noted above, once the EAC is established, the adequacy of the study design to assess comparability must be evaluated. This work is performed before the new process data are collected. Study design and sample-size calculations are critical when conducting a statistical test. As in all statistical investigations, there is a possibility that the conclusions may be incorrect. In the context of an equivalence test, two different errors exist. The first error takes the form of a false positive—declaring two processes are equivalent when they are in fact not equivalent. This is called a type 1 error and represents the risk to the consumer, because stating that the two processes are equivalent when they are not could possibly compromise efficacy or patient safety. The second error is a false negative, which is declaring that two processes are not equivalent when they are in fact equivalent. This is the type 2 error. The type 2 error represents the manufacturer's risk, becuase not claiming equivalence when equivalence exists will result in unnecessary delays in the implementation of the change. Table I organizes the declarative statement concerning equivalence relative to the true state of nature with the corresponding error type.

For an equivalence test, the type 1 error is generally set at 5%. This represents the statistical test size and is the reason why the 90% confidence interval is computed in the testing process (5). Once the type 1 error rate is established, the desired type 2 error is obtained by selecting an appropriate number of new lots.

One advantage of the statistical equivalence approach is that the type 1 error rate (i.e., consumer risk) is established at the desired level and is not a function of the total sample size. Thus, the consumer is always protected at the desired level. The type 2 error is controlled through appropriate study design. When an experimental design has an adequate number of lots, the investigator is rewarded for proper experimental planning.


Table 2
For the example, the type 1 error is set at 5%. In general, if the desired type 1 error is X%, a two-sided 100-2X% confidence interval is required in the equivalence test. The type 2 error is computed under different study designs for comparing new lots to the four historical lots. The type 2 error is computed assuming the true difference between slopes is 0 and also when the true difference in slopes is 25% of the EAC (0.25% per month) and 50% of the EAC (0.5% per month). Table II lists the type 2 error rates for these different scenarios. These error rates were computed using computer simulation and the estimated variances of the historical data.

Based on the information in Table II, four new lots provided adequate control of the type 2 error with measurements to be taken at 0, 2, 4, and 6 months for each of the four lots.




Once the EAC and sample design have been established, it is helpful to represent the EAC graphically. Algebraically, equivalence is demonstrated if

where bHistoric is the average slope estimate of the historical process lots, bNews is the average slope estimate of the new process lots, and ME is the margin of error for a two-sided 90% confidence interval. The formula for the margin of error depends on the assumed statistical design. A formula is given for one particular case in the numerical example that follows.




Equation (1) can be rewritten as


Figure 3. Average slope of the historical process with graphical representation of equivalence acceptance criteria (EAC). Equivalence is demonstrated if new process average slope falls within red lines.
Figure 3 plots the average slope for the historical process (bHistoric) for the four lots shown in Figure 2 with a y-intercept equal to the average of the y-intercepts across all four lots. The two red lines have the same y-intercept, but with slopes of (bHistoric)–EAC+ME and (bHistoric)+EAC–ME. If the average slope for the new process lots (bNews) falls within the red lines, then Equation 2 is satisfied, and equivalence of average slope is demonstrated. In this example, ME = 0.371%, (bHistoric) = –1.13% per month, y-intercept = 89.5%, and EAC = 1% per month. For purposes of Figure 3, ME is estimated using the variance estimates of only the historical data. The final value for ME will include variance estimates from both the historical and new processes.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

NIH Launches Human Safety Study of Ebola Vaccine Candidate
August 29, 2014
Suppliers Seek to Boost Single-Use Technology
August 21, 2014
Bristol-Myers Squibb and Celgene Collaborate on Immunotherapy and Chemotherapy Combination Regimen
August 20, 2014
FDA Warns about Fraudulent Ebola Treatments
August 15, 2014
USP Awards Analytical Research
August 15, 2014
Author Guidelines
Source: BioPharm International,
Click here